- Home
- ACRV vs OTLK Comparison
ACRV vs OTLK Comparison
Compare ACRV & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- OTLK
- Stock Information
- Founded
- ACRV 2018
- OTLK 2010
- Country
- ACRV United States
- OTLK United States
- Employees
- ACRV N/A
- OTLK N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRV Health Care
- OTLK Health Care
- Exchange
- ACRV Nasdaq
- OTLK Nasdaq
- Market Cap
- ACRV 47.8M
- OTLK 48.3M
- IPO Year
- ACRV 2022
- OTLK 2016
- Fundamental
- Price
- ACRV $1.52
- OTLK $1.04
- Analyst Decision
- ACRV Buy
- OTLK Buy
- Analyst Count
- ACRV 7
- OTLK 5
- Target Price
- ACRV $17.40
- OTLK $8.50
- AVG Volume (30 Days)
- ACRV 3.4M
- OTLK 8.2M
- Earning Date
- ACRV 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- ACRV N/A
- OTLK N/A
- EPS Growth
- ACRV N/A
- OTLK N/A
- EPS
- ACRV N/A
- OTLK N/A
- Revenue
- ACRV N/A
- OTLK $1,505,322.00
- Revenue This Year
- ACRV N/A
- OTLK N/A
- Revenue Next Year
- ACRV $805.34
- OTLK $484.88
- P/E Ratio
- ACRV N/A
- OTLK N/A
- Revenue Growth
- ACRV N/A
- OTLK N/A
- 52 Week Low
- ACRV $1.05
- OTLK $0.79
- 52 Week High
- ACRV $10.00
- OTLK $7.26
- Technical
- Relative Strength Index (RSI)
- ACRV 56.53
- OTLK 36.12
- Support Level
- ACRV $1.30
- OTLK $0.90
- Resistance Level
- ACRV $2.67
- OTLK $1.19
- Average True Range (ATR)
- ACRV 0.19
- OTLK 0.23
- MACD
- ACRV 0.02
- OTLK -0.06
- Stochastic Oscillator
- ACRV 16.06
- OTLK 9.62
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.